Introduction {#sec1_1}
============

The outbreak of coronavirus disease 2019 (CO­VID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), started in Wuhan (Hubei Province, People\'s Republic of China) \[[@B1]\]. On December 31, 2019, twenty-seven cases of pneumonia of unknown cause were reported to the World Health Organisation \[[@B1]\]. COVID-19 was identified as the underlying cause \[[@B2]\]. The first Chinese COVID-19-related death was reported on January 9, 2020. SARS-CoV-2 quickly spread to other Chinese provinces and neighbouring countries \[[@B1]\]. The French authorities confirmed the first "imported" CO­VID-19 case on January 24, 2020, which represented the official arrival in Europe \[[@B3]\]. The number of COVID-19 patients quickly rose within Europe, and in Italy in particular, where the so-called "patient zero" remains unknown \[[@B4]\]. On March 11, 2020, the outbreak qualified as a pandemic \[[@B5]\].

In Belgium, the first imported case was confirmed on February 4, 2020, represented by a businessman returning from China \[[@B6]\]. The number of Belgian patients quickly rose after the February holidays, as many winter sport tourists returned from COVID-19-affected areas in Austria and Italy \[[@B7]\]. The first Belgian COVID-19-related death was reported on March 11, 2020, and along with the spread of the infection, mortality rates quickly increased \[[@B8]\]. In response to this pandemic, unprecedented public health actions were proclaimed, including social distancing, hygienic measures, travel restrictions and quarantine \[[@B9]\]. All measures had to protect the hospitals and their intensive care units from being flooded by a sudden peak of COVID-19 patients, a process which was designated as "flattening the curve." The Belgian National Security Council declared a national state of emergency on March 12, 2020: schools, universities and non-food shops were closed, and teleworking was recommended wherever possible \[[@B10]\]. A relative confinement started, allowing people to leave the house only for grocery shopping, visiting pharmacies and medical doctors for urgent matters, and commuting (if employed in essential food- and health care-associated businesses) \[[@B10]\].

The Belgian government obliged all hospitals to announce a "Hospital Emergency Plan" (HEP) on March 14, 2020, thereby postponing all non-urgent consultations and operations. This measure had to prevent non-COVID-19 patients from being infected with SARS-CoV-2. Although this measure was supported by the majority of the medical staff, critical voices put forward that the collateral damage caused by this health care delay might transcend the COVID-19-related morbidity and mortality \[[@B11], [@B12], [@B13]\]. The HEP lasted for 7 weeks and was abrogated on May 4, 2020.

In this report, we investigated the impact of the governmental anti-COVID-19 measures on the workload of a Belgian academic laboratory for histopathology and cytopathology. By comparing the organ-specific number of biopsies, cytological samples and surgical specimens between 2020 and the previous years, we aimed to identify which health care domains were most severely affected by postponed care. We attempted to provide recommendations for future "deconfinement" health care actions, thereby minimizing the potential negative effects of the anti-COVID-19 measures.

Materials and Methods {#sec1_2}
=====================

This study was performed in the Department of Pathology of the Cliniques universitaires Saint-Luc (Brussels, Belgium). Overall sample numbers were retrieved from the software for electronic histopathological reports (LIS DaVinci, MIPS, Ghent, Belgium). Monthly amounts were compared for the first trimester of 2017--2020 for a representative selection of sample types and immunohistochemical stains. The following samples were selected: colon biopsies, gastric biopsies, cervical cytology, cervical biopsies, skin biopsies, pulmonary biopsies performed by endobronchial ultrasound (EBUS), bone marrow biopsies, mammary surgical specimens (comprising lumpectomies, quadrantectomies and mastectomies), breast biopsies, surgical thyroid specimens, prostate biopsies, appendectomy specimens, resections of the lower digestive tract and neuropathological biopsies. The following immunohistochemical stains were selected: CD3, CD34, cytokeratin-7 (CK-7), CK-20, oestrogen receptor, HER2, *Helicobacter pylori*, Ki67, p16, p53, p63 and S100. This selection was based on the number of pathologists requesting a particular stain, as well as the request frequency, to ensure that all subspecialties were represented by this selection. For instance, immunohistochemistry for *H. pylori* is the most frequently requested stain in our laboratory, and S100 is regularly requested by pathologists practicing soft tissue, head and neck, dermato- and neuropathology. The number of tests for dual-probe silver-enhanced in situ hybridisations for HER2/CEP17 were retrieved. The number of demands from external laboratories for any type of molecular analysis, comprising in situ hybridisation, human papillomavirus typing and targeted next-generation sequencing, was determined. The monthly total number of paraffin blocks and glass slides was retrieved using Ventana Vantage (Roche Diagnostics, Basel, Switzerland), for the first trimester of 2017--2020.

All data were exported to Microsoft Excel (Redmond, WA, USA). The number of slides, blocks, samples, stains or molecular tests per month per year was compared by using contingency tables and χ^2^ tests. Statistical analyses were performed using the online χ^2^ contingency table calculator of the Physics Department of the College of Saint Benedict and Saint John\'s University (St. Joseph and Collegeville, MN, USA) \[[@B14]\]. The significance level was set at \<0.05. This study did not involve experiments on human subjects or animals nor any experiments requiring residual tissue material. This study is therefore exempt from approval by the local ethics committee, in accordance with institutional guidelines.

Results {#sec1_3}
=======

Overall Impact of COVID-19 on the Pathology Workload and Staff {#sec2_1}
--------------------------------------------------------------

In March 2020, the total number of samples received by our laboratory was reduced by 35% when compared with January and February 2020, which equalled a reduction of 40--45% in comparison with the 3 previous years. The number of paraffin blocks was reduced by 27--35% and the number of slides by 16--17% when compared with March of the 3 previous years (Table [1](#T1){ref-type="table"}). In April 2020, the total number of samples decreased by 72% when compared with January and February 2020, and by around 70% when compared with the same month of the previous years. The number of paraffin blocks diminished by 54--59% and the number of slides by 47--53% in comparison with April of the previous years. The absolute number of complaints by technical staff concerning issues with paraffin blocks, such as presence of staplers, insufficient decalcification or insufficient formalin fixation, diminished by 47% in April 2020. Such technical issues are less likely to occur with biopsies than with surgical resection specimens. This explains why the relative number of complaints (i.e., the percentage of paraffin blocks with a complaint concerning a technical issue) rose by 84% in April 2020: surgical resection specimens took a larger share of the total number of samples, as the number of biopsies was strongly reduced.

Since our laboratory also receives histological and cytological samples from external non-academic hospitals, the total number of samples could have been influenced by a change of contracts with these external hospitals during the period 2017--2020. We therefore investigated whether the amount of internal samples had been affected in a similar way. For January and February 2020, a respective 6% and an 8% increase in internal samples were noted upon comparison with 2019. After comparison of March and April 2020 versus March and April 2019, we noted an 8.5 and 57% reduction of internal samples, respectively. Despite a slight increase in April 2020, the number of autopsies was not statistically significantly different throughout the investigated time period. In the first trimester of 2020, thirteen autopsies were SARS-CoV-2-related.

We analysed the financial impact of the sample reduction during the national HEP (i.e., weeks 12--18 of 2020), including the 2 weeks before (Fig. [1a](#F1){ref-type="fig"}). When the HEP was announced, the income of the laboratory decreased by 43% as compared with the same week in 2019. During the fourth week of the HEP, this decrease amounted to 66% and was slowly restored thereafter. The reduced income forced us to introduce furlough for 5--10% of technical and administrative staff (Fig. [1b](#F1){ref-type="fig"}). Simultaneously, around 8--12% of technical staff were outsourced to the virology laboratory during weeks 3--7 of the HEP, as this department faced a substantially increased workload due to SARS-CoV-2 testing. Sick leave amounted to 17--22% in the first 2 weeks of the HEP, and slowly decreased in the weeks thereafter. Technical and administrative staff were encouraged to take up a part of their annual holidays during this period, to prevent being sent on furlough, and to prevent a lack of staff during the summer holidays, as we foresee a potential rebound effect on the laboratory workload during the "deconfinement period."

COVID-19 Impact on the Number of Samples {#sec2_2}
----------------------------------------

Figures [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"} illustrate the samples per month per year for a particular sample type. Since the COVID-19 pandemic covers the first trimester of 2020 so far, all data are limited to this 4-month-period for the years 2017 till 2020. The exact numbers per sample type are provided in Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}. For each sample type, a substantial reduction was noted in March and April 2020, although this decrease was not statistically significant for the prostate biopsies, appendectomies, low gastrointestinal tract resection specimens, bone marrow biopsies and central nervous system samples. Oncological surgery was considered urgent and was therefore allowed to continue. Nevertheless, breast surgical activities were halved in April 2020. For pulmonary EBUS biopsies, a 100% increase was noted in March 2020 as compared with the same month of the previous years, followed by a reduction of around 82% in April 2020. Surgical interventions related to the central nervous system remained relatively stable over time. Non-gynaecological cytology was reduced by 45% in March and 61% in April.

COVID-19 Impact on the Number of Immunohistochemical and Molecular Tests {#sec2_3}
------------------------------------------------------------------------

We selected a panel of 12 immunohistochemical stains to investigate the impact of the anti-COVID-19 measures (Table [4](#T4){ref-type="table"}). In March 2020, there was no impact on the amount of immunohistochemistry, except for p53 and *H. pylori*, which were halved when compared with March 2019 and March 2018. In April 2020, we noted a significant decrease for most immunohistochemical stains when compared with April of the previous years, with the exception of CK-7, CK-20, Ki67, p16 and S100. Some stains (such as CK-7 and p16) presented with a significantly altered request frequency since 2017, which we can only explain by differences in pathologists\' individual request behaviour (Fig. [3](#F3){ref-type="fig"}); this Figure illustrates the number of external demands for any type of molecular test. This number was lower in April 2020 than in March 2020 but did not substantially differ from the amount of external demands in the previous years. The number of *HER2* silver-enhanced in situ hybridisations, a technique used for the investigation of the amplification status of the *HER2* gene in breast cancer and gastric cancer, almost halved in April 2020 in comparison with April 2019.

Discussion {#sec1_4}
==========

The unprecedented announcement of a 7-week-lasting national HEP in Belgium to cope with the COVID-19 pandemic offered a unique opportunity to investigate the impact of these measures on the workload of an academic laboratory for histo- and cytopathology. As this workload indirectly reflects various medical interventions, this study enabled us to identify areas for "deconfinement" health care actions. Overall, laboratory activities in the first trimester of the year are higher in March than in April. This is explained by the annual 2-week Easter holidays that reduce overall medical and laboratory activities. The national HEP started mid-March and lasted till May 4, 2020. The workload reduction is therefore most pronounced in April. Although urgent medical consultations and operations were allowed to continue as long as the intensive care units could cope with the number of COVID-19 patients \[[@B15], [@B16], [@B17]\], we noted a significant decrease in the number of breast resection specimens and pulmonary EBUS biopsies. However, the number of external demands for molecular tests did not decline in our centralised laboratory. This reflects the continued care for cancer patients. Although Malapelle et al. \[[@B18]\]described a substantial shift from next-generation sequencing towards fully automated molecular pathology, a similar shift was not observed in our laboratory. We do not perform germline mutation testing, but Minucci et al. \[[@B19]\] previously described a COVID-19-related decline in genomic diagnostics. As many countries start to ease the COVID-19-related confinement measures and cancer screening programmes restart, an incoming wave of undetected malignancies is expected \[[@B20]\]. Our study indirectly supports this assumption, as cancer screening-related samples were severely affected by the HEP.

The temporary annulation of the national breast cancer screening programme for women aged 50--70 explains the diminished number of breast biopsies and surgeries. Symptomatic patients, presenting with a palpable lump and/or nipple discharge and/or skin retraction were further investigated, but during the HEP, no breasts were biopsied for suspicious clusters of calcifications on screening mammograms. All aesthetic breast surgery was postponed. Similarly, no colonoscopies were performed to investigate positive immunochemical faecal occult blood tests (iFOBT). Since 2013, all Belgian men and women aged 56--74 are invited for a biannual immunochemical faecal occult blood test \[[@B21], [@B22]\]. Since 2020, screening starts at the age of 50 \[[@B23], [@B24], [@B25]\]. A positive immunochemical faecal occult blood test is generally followed by colonoscopy, to exclude colorectal polyps and carcinomas \[[@B26]\]. These colonoscopies were considered as non-urgent, which is reflected in the reduction of colon biopsies.

A third Belgian (pre)cancer screening programme consists of triannual cervical smears for women aged 25--64 \[[@B27]\]. Both cervical and non-gynaecological cytology rates dramatically collapsed during the HEP. A similar COVID-19-related reduction in cytology samples was observed in Italy \[[@B28]\].

At present, there is no organised prostate cancer screening programme in Belgium. However, many general practitioners screen for prostate cancer by determining the prostate-specific antigen level, which can result in further investigation by medical imaging and prostate biopsies \[[@B29], [@B30]\]. Although not statistically significant, we observed a decline in prostate biopsies, which may reflect the reduced prostate-specific antigen screening activities. Similarly, patients at high risk for dysplastic naevi and melanoma are generally followed up by a dermatologist. Since most skin conditions were considered non-urgent, the activities of many dermatologists dropped to zero, which was reflected in the strongly reduced number of skin biopsies. Biopsies, cytology and resection specimens that are commonly related to functional pathology also diminished.

Overall, the total number of slides and tissue blocks, as well as the number of immunohistochemical stains, was not affected as severely as the overall sample number. This reflects the complexity of the samples we continued to receive: in the first place, the number of cytological samples and biopsies diminished, whereas oncology-related resection specimens were continued. Since a surgical resection specimen requires more tissue blocks than a single biopsy specimen, the total number of blocks did not extremely diminish. Oncology-related histopathological samples often require multiple immunohistochemical stains to establish a final diagnosis. Therefore, the overall immunohistochemical load was less affected than the total workload or the total number of samples. The relative overrepresentation of surgical specimens was also reflected in the relative increase in complaints made by technical staff concerning technical issues with tissue blocks: although the absolute number of complaints decreased along with the decreased number of samples, the relative number of complaints rose by 84% in April, because the ratio of biopsies versus specimens altered. All data reported here were repetitively discussed during biweekly staff meetings, for which conferencing software was implemented \[[@B31]\].

Lastly, we did not observe a substantially increased number of autopsies in the first trimester of 2020. The COVID-19 outbreak poses new challenges for the safety of the operators \[[@B32], [@B33]\]. In the absence of a positive COVID-19 test, all deceased patients were still considered as potentially infected, and all post-mortem studies were performed in accordance with international guidelines concerning biosafety measures for autopsies on SARS-CoV-2-positive deceased patients \[[@B34], [@B35]\].

Conclusion {#sec1_5}
==========

The national emergency state announced by the Belgian government to contend the COVID-19 pandemic provided an unrivalled opportunity to investigate the impact of a viral pandemic on the management of cancer screening programmes. Several areas in medicine were affected by the anti-COVID-19 measures. Although the numbers of a single laboratory are too small to generate robust conclusions for an entire nation, we feel that they do give an impression of the general impact of the national anti-COVID-19 measures. Sample types issued from cancer screening programmes seem most severely decreased. Health care actions during the deconfinement period should focus on restarting cancer screening programmes. Health care professionals should assure that patient contacts related to cancer screening are postponed instead of cancelled, to limit the number of patients that slips through the cracks of the screening network.
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![**a** Graph illustrating the reduced income in 2020 as compared to 2019 during the period of the Belgian Hospital Emergency Plan (HEP) in correlation with the reduced technical and administrative staff of the Department of Pathology. The HEP started in week 12 of 2020. **b** Graph illustrating the causes of absent technical staff as a function of time during the HEP (weeks 12--18 of 2020).](pat-0001-g01){#F1}

![Graphs illustrating the decline of the number of samples per month, for colon biopsies (**a**), gastric biopsies (**b**), cervical cytology (**c**), prostate biopsies (**d**), skin biopsies (**e**) and EBUS biopsies (**f**).](pat-0001-g02){#F2}

![Graphs illustrating the decline of the number of samples per month, for breast resections (**a**), thyroidectomies (**b**), resections of the lower gastrointestinal (GI) tract (**c**), appendectomy specimens (**d**), bone marrow biopsies (**e**) and external demands for any type of molecular test (**f**).](pat-0001-g03){#F3}

###### 

Overview of the monthly total number of samples, tissue blocks and slides per year for the first trimester

                                    Jan      Feb      Mar       Apr       *p*
  --------------------------------- -------- -------- --------- --------- -----
  *Total number of samples*                                     \<0.001   
  2017                              6,042    6,098    6,835     5,317     
  2018                              6,305    5,733    6,658     5,616     
  2019                              6,287    6,290    6,011     5,448     
  2020                              5,856    5,374    3,723     1,585     
                                                                          
  *Total number of tissue blocks*                     \<0.001             
  2017                              8,577    8,198    9,016     7,133     
  2018                              7,622    6,577    7,966     6,533     
  2019                              7,176    7,266    7,957     7,512     
  2020                              6,698    7,444    5,806     3,069     
                                                                          
  *Total number of slides*                                      \<0.001   
  2017                              18,397   17,720   19,755    16,348    
  2018                              18,926   15,921   19,952    16,470    
  2019                              18,950   18,080   19,403    18,160    
  2020                              19,161   18,423   16,467    8,676     
                                                                          
  *Foetal and adult autopsies*                                  0.759     
  2017                              8        4        5         9         
  2018                              5        5        6         6         
  2019                              12       7        9         5         
  2020                              10       9        7         14        

###### 

Monthly number of samples per year for the first trimester

                                  Jan     Feb     Mar       Apr     *p*
  ------------------------------- ------- ------- --------- ------- ---------
  *Colon biopsies*                                                  \<0.001
  2017                            417     391     478       371     
  2018                            429     411     450       383     
  2019                            400     385     390       373     
  2020                            443     390     207       55      
                                                                    
  *Gastric biopsies*                                                \<0.001
  2017                            905     873     954       727     
  2018                            811     721     811       656     
  2019                            743     804     830       771     
  2020                            678     613     323       62      
                                                                    
  *Non-gynaecological cytology*                   \<0.001           
  2017                            538     560     579       530     
  2018                            592     516     654       579     
  2019                            552     526     565       568     
  2020                            518     486     327       220     
                                                                    
  *Cervical cytology*                                               \<0.001
  2017                            1,598   1,473   1,690     1,206   
  2018                            1,738   1,551   1,595     1,288   
  2019                            1,583   1,600   1,521     1,237   
  2020                            1,310   1,142   675       243     
                                                                    
  *Cervical biopsies*                                               \<0.001
  2017                            42      38      67        45      
  2018                            55      42      49        43      
  2019                            51      56      47        45      
  2020                            68      48      34        15      
                                                                    
  *Skin biopsies*                                                   \<0.001
  2017                            881     920     920       674     
  2018                            1,023   812     883       789     
  2019                            1,079   924     938       760     
  2020                            1,226   1,077   634       170     
                                                                    
  *Thyroidectomies*                                                 0.008
  2017                            20      11      21        26      
  2018                            27      18      29        19      
  2019                            25      25      19        23      
  2020                            21      20      7         8       
                                                                    
  *Prostate biopsies*                                               0.065
  2017                            30      19      28        14      
  2018                            31      20      17        23      
  2019                            30      25      13        27      
  2020                            13      16      8         6       

###### 

Monthly number of samples per year for the first trimester

                                       Jan   Feb   Mar     Apr     *p*
  ------------------------------------ ----- ----- ------- ------- ---------
  *Breast resections*                                              \<0.001
  2017                                 42    57    43      35      
  2018                                 31    14    26      40      
  2019                                 41    45    59      48      
  2020                                 39    50    41      21      
                                                                   
  *Breast biopsies*                                                \<0.001
  2017                                 41    50    57      35      
  2018                                 41    51    52      45      
  2019                                 60    89    57      45      
  2020                                 33    31    30      10      
                                                                   
  *Appendectomies*                                                 0.188
  *2017*                               34    32    43      35      
  2018                                 33    24    35      26      
  2019                                 24    25    26      26      
  2020                                 27    27    11      18      
                                                                   
  *Lower digestive tract resections*               0.628           
  2017                                 41    52    53      45      
  2018                                 32    36    43      40      
  2019                                 41    37    44      35      
  2020                                 33    30    25      19      
                                                                   
  *EBUS biopsies*                                                  \<0.001
  2017                                 9     17    25      13      
  2018                                 7     18    21      12      
  2019                                 4     17    12      25      
  2020                                 31    18    38      3       
                                                                   
  *CNS biopsies and resections*                            0.749   
  2017                                 46    35    51      40      
  2018                                 39    35    43      42      
  2019                                 25    27    31      28      
  2020                                 29    37    28      26      
                                                                   
  *Bone marrow biopsies*                                   0.639   
  2017                                 48    42    39      29      
  2018                                 73    64    69      52      
  2019                                 66    46    42      39      
  2020                                 38    36    20      20      

CNS, central nervous system; EBUS, endobronchial ultrasound.

###### 

Monthly number of tests per year for the first trimester

                                           Jan   Feb   Mar     Apr   *p*
  ---------------------------------------- ----- ----- ------- ----- ---------
  *CD3*                                                              \<0.001
  2017                                     79    78    89      100   
  2018                                     191   177   204     160   
  2019                                     175   199   186     177   
  2020                                     225   236   221     106   
                                                                     
  *CD34*                                                             \<0.001
  2017                                     43    47    39      30    
  2018                                     49    28    53      47    
  2019                                     48    41    60      42    
  2020                                     55    69    32      29    
                                                                     
  *CK-7*                                                             0.013
  2017                                     148   136   152     106   
  2018                                     80    50    86      71    
  2019                                     51    52    59      54    
  2020                                     61    67    45      66    
                                                                     
  *CK-20*                                                            0.057
  2017                                     30    31    23      21    
  2018                                     24    13    26      28    
  2019                                     22    32    22      19    
  2020                                     32    20    22      15    
                                                                     
  *ER*                                                               0.022
  2017                                     75    79    75      53    
  2018                                     103   101   111     99    
  2019                                     95    139   145     104   
  2020                                     116   92    116     69    
                                                                     
  *HER2*                                                             0.003
  2017                                     78    71    71      40    
  2018                                     57    71    51      65    
  2019                                     57    82    85      56    
  2020                                     53    36    54      30    
                                                                     
  *HP*                                                               \<0.001
  2017                                     511   590   611     461   
  2018                                     465   481   544     425   
  2019                                     439   493   497     479   
  2020                                     438   371   270     37    
                                                                     
  *Ki67*                                                             0.054
  2017                                     175   176   193     159   
  2018                                     147   171   185     176   
  2019                                     169   194   206     163   
  2020                                     163   158   152     103   
                                                                     
  *p16*                                                              0.004
  2017                                     113   80    111     85    
  2018                                     98    103   73      81    
  2019                                     65    88    88      63    
  2020                                     78    90    65      46    
                                                                     
  *p53*                                                              \<0.001
  2017                                     77    78    72      77    
  2018                                     78    78    138     82    
  2019                                     79    81    119     73    
  2020                                     100   85    62      50    
                                                                     
  *p63*                                                              0.004
  2017                                     17    16    8       11    
  2018                                     14    7     26      16    
  2019                                     23    24    16      6     
  2020                                     10    10    16      7     
                                                                     
  *S100*                                                             0.151
  2017                                     67    49    47      44    
  2018                                     50    37    34      39    
  2019                                     30    38    50      29    
  2020                                     45    42    53      38    
                                                                     
  *External demands for molecular tests*               0.005         
  2017                                     76    48    49      32    
  2018                                     45    61    58      59    
  2019                                     85    92    84      64    
  2020                                     98    83    101     56    
                                                                     
  *HER2 SISH*                                                        \<0.001
  2017                                     73    54    68      44    
  2018                                     87    87    106     111   
  2019                                     72    79    77      71    
  2020                                     92    37    68      39    

CK, cytokeratin; ER, oestrogen receptor; HP, *Helicobacter pylori*; SISH, silver-enhanced in situ hybridisation.
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